Vui Pham
YOU?
Author Swipe
View article: Surgical Management of Male Urinary Incontinence Following Radiation Therapy for Prostate Cancer: A Review
Surgical Management of Male Urinary Incontinence Following Radiation Therapy for Prostate Cancer: A Review Open
Purpose of Review This review evaluates the surgical management of male urinary incontinence (UI) following radiation therapy (RT) for prostate cancer, focusing on artificial urinary sphincters (AUS) and male urethral slings. It aims to as…
View article: Supplementary Figure 1 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy
Supplementary Figure 1 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy Open
PDF file - 191K, Tumor HPV status and serum TGF-beta1 levels of HNSCC patients
View article: Data from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy
Data from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy Open
EGF receptor (EGFR)–targeted monoclonal antibodies (mAb), such as cetuximab, execute their antitumor effect in vivo via blockade of receptor–ligand interactions and engagement of Fcγ receptors on immune effector cells that trigger antibody…
View article: Supplementary Figure 1 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy
Supplementary Figure 1 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy Open
PDF file - 191K, Tumor HPV status and serum TGF-beta1 levels of HNSCC patients
View article: Supplementary Table 2 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy
Supplementary Table 2 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy Open
PDF file - 70K, A, Serum levels of the indicated cytokines in patients with HNSCC and pleomorphic adenoma (non-cancer control). B, Comparison of serum TGF-beta1 levels in non-cancer controls and patients with HNSCC at the time of new diagn…
View article: Supplementary Table 2 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy
Supplementary Table 2 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy Open
PDF file - 70K, A, Serum levels of the indicated cytokines in patients with HNSCC and pleomorphic adenoma (non-cancer control). B, Comparison of serum TGF-beta1 levels in non-cancer controls and patients with HNSCC at the time of new diagn…
View article: Supplementary Table 1 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy
Supplementary Table 1 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy Open
PDF file - 256K, Clinical characteristics of patients with HNSCC
View article: Data from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy
Data from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy Open
EGF receptor (EGFR)–targeted monoclonal antibodies (mAb), such as cetuximab, execute their antitumor effect in vivo via blockade of receptor–ligand interactions and engagement of Fcγ receptors on immune effector cells that trigger antibody…
View article: Supplementary Table 1 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy
Supplementary Table 1 from Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy Open
PDF file - 256K, Clinical characteristics of patients with HNSCC
View article: Milk derived colloid as a novel drug delivery carrier for breast cancer
Milk derived colloid as a novel drug delivery carrier for breast cancer Open
Triple negative breast cancer has an extremely poor prognosis when chemotherapy is no longer effective. To overcome drug resistance, novel drug delivery systems based on nanoparticles have had remarkable success. We produced a novel nanopa…